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Polycystic ovary syndrome (PCOS) is associated with infertility, increased androgen lev-
els, and insulin resistance. In adipose tissue, zinc facilitates insulin signaling. Circulating 
zinc levels are altered in obesity, diabetes, and PCOS; and zinc supplementation can 
ameliorate metabolic disturbances in PCOS. In adipose tissue, expression of zinc influx 
transporter ZIP14 varies with body mass index (BMI), clinical markers of metabolic syn-
drome, and peroxisome proliferator-activated receptor gamma (PPARG). In this study, 
we investigated expression levels of ZIP14 and PPARG in subcutaneous adipose tissue 
of 36 PCOS women (17 lean and 19 obese women) compared with 23 healthy controls 
(7 lean and 16 obese women). Further, expression levels of zinc transporter ZIP9, a 
recently identified androgen receptor, and zinc efflux transporter ZNT1 were investigated, 
alongside lipid profile and markers of glucose metabolism [insulin degrading enzyme, 
retinol-binding protein 4 (RBP4), and glucose transporter 4 (GLUT4)]. We find that ZIP14 
expression is reduced in obesity and positively correlates with PPARG expression, which 
is downregulated with increasing BMI. ZNT1 is upregulated in obesity, and both ZIP14 
and ZNT1 expression significantly correlates with clinical markers of altered glucose 
metabolism. In addition, RBP4 and GLUT4 associate with obesity, but an association 
with PCOS as such was present only for PPARG and RBP4. ZIP14 and ZNT1 does not 
relate to clinical androgen status and ZIP9 is unaffected by all parameters investigated. 
In conclusion, our findings support the existence of a zinc dyshomeostasis in adipose 
tissue in metabolic disturbances including PCOS-related obesity.
Keywords: obesity, polycystic ovary syndrome, peroxisome proliferator-activated receptor gamma, slc30a, 
slc39a, ZiP14, ZNT1, zinc
Abbreviations: BMI, body mass index; DHT, dihydrotestosterone; GLUT4, glucose transporter 4; HDL, high-density lipopro-
tein; HOMA index, homeostatic model assessment; IDE, insulin degrading enzyme; LDL, low-density lipoprotein; LRP10, low-
density lipoprotein receptor-related protein-10; PCOS, polycystic ovary syndrome; PPARG, peroxisome proliferator-activated 
receptor gamma; RBP4, retinol-binding protein 4; SHBG, sex hormone-binding globulin; VLDL, very-low-density lipoprotein.
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inTrODUcTiOn
Polycystic ovary syndrome (PCOS) is the most common cause 
of infertility, affecting approximately 12−18% of all women of 
reproductive age (1). The syndrome is linked to increased risk 
of cardiovascular disease and type 2 diabetes (2). High androgen 
levels and oligo/anovulation are characteristics of PCOS, as are 
metabolic disturbances such as insulin resistance, visceral obe-
sity, and dyslipidemia (2).
Altered serum-zinc levels are found in women with PCOS 
compared to body weight-matched, healthy controls, and both 
increased and decreased zinc levels have been reported (3–5). 
Interestingly, 8  weeks of zinc supplementation has beneficial 
effects on fasting plasma glucose, insulin resistance as measured 
by homeostatic model assessment (HOMA index), and the 
lipid profile in PCOS women (6). Similar to PCOS, a disturbed 
zinc homeostasis is also common in type 2 diabetic and obese 
individuals, which is evident by the presence of hypozincemia 
(7–10). Low zinc intake in obese individuals has been linked to 
hyperinsulinemia, increased low-grade inflammation, and an 
aggravated lipid profile (11). These results indicate the presence of 
a disturbed zinc homeostasis in PCOS women, potentially linked 
with their obesity, and with an adverse effect on their metabolic 
health.
The essential trace metal zinc is required for the function 
of more than 300 enzymes and with an effect on at least 2,000 
transcription factors (12). Free cytoplasmic zinc also regulates 
gene expression through the metal-responsive transcription 
factor-1 (13) and the level of free zinc can affect intracellular 
signaling pathways, e.g., by inhibition of protein tyrosine phos-
phatase (14). Due to its intracellular signaling and structural 
functions, zinc plays a role in lipid and glucose metabolism as 
well as in fertility (12, 15). Zinc can activate the insulin signaling 
pathway through inhibition of protein tyrosine phosphatase 
leading to increased phosphorylation of the insulin receptor 
(14). Further, zinc ions can work in an insulinomimetic way 
within adipocytes, stimulating lipogenesis and glucose trans-
port through translocation of glucose transporter 4 (GLUT4) 
to the cell membrane (16, 17). In the reproductive system, zinc 
deficiency associates with poor pregnancy outcomes and zinc is 
crucial for normal sexual development in both men and women 
(12, 18–21). Animal studies show that zinc deficiency affects 
ovulation, as well as zinc has an effect on the estrogen level and 
menstrual cycle (22, 23). In men, zinc deficiency is linked to 
decreased circulating levels of testosterone and dihydrotestos-
terone (DHT) (23).
The regulation of intracellular zinc homeostasis is maintained 
by a number of zinc transporters and metallothioneins (24, 25). 
Fourteen human zinc influx transporters (SLC39a; ZIP1–14) and 
10 zinc-efflux transporters (SLC30a; ZNT1–10) have so far been 
identified (24, 25).
The zinc influx transporter ZIP14 is a member of the LIV-1 
subfamily of zinc transporters that localize to the plasma 
membrane and facilitate the transport of zinc into the cell (26). 
ZIP14 is believed to be important in adipogenesis (27–29). We 
recently reported that ZIP14 expression in adipose tissue is 
reversibly downregulated by obesity and inversely correlated 
with clinical markers of metabolic disease (27). Further, 
we found a possible link between ZIP14 expression and the 
transcription factor peroxisome proliferator-activated receptor 
gamma (PPARG) in humans (27), a finding also seen in stud-
ies of adipose tissue from Zip14 knockout mice (29). PPARG 
regulates lipid uptake and glucose metabolism, and plays an 
essential role in adipogenesis (30). Polymorphisms in the 
PPARG gene have been shown to decrease the risk and affect 
the metabolic phenotype of PCOS (31, 32) and the function 
of PPARG is regulated by zinc status (33, 34). Similar to other 
members of the LIV-1 subfamily of zinc transporters, estrogen 
can induce zinc influx through ZIP14 (26, 35, 36) and another 
zinc influx transporter, ZIP9, has recently been identified as 
an androgen receptor in human hormone-responsive breast 
and prostate cancer cells, with androgens stimulating ZIP9-
mediated zinc influx (37, 38).
In this study, we aimed at investigating if intracellular 
zinc dyshomeostasis, as reflected by changes in expression of 
zinc transporters, is directly linked to the PCOS syndrome. 
Specifically, we aimed at investigating the expression levels of 
ZIP14, due to its indicated role in adipose tissue functioning and 
association with metabolic disease. A potential sex-hormonal 
and metabolic regulation of ZIP14, as a member of the LIV-1 
subfamily, were investigated together with the expression levels 
of the androgen receptor ZIP9 and the main zinc efflux trans-
porter ZNT1, in adipose tissue from lean and obese women 
with PCOS as well as weight-matched controls. The expres-
sion levels were correlated with clinical markers of lipid and 
glucose metabolism, androgen status, as well as expression of 
genes related to glucose metabolism within adipose tissue, i.e., 
GLUT4, insulin degrading enzyme (IDE), and retinol-binding 
protein 4 (RBP4), all speculated to be involved in metabolic 
disease.
MaTerials anD MeThODs
Participants and interventions
Thirty-six lean [body mass index (BMI)  =  18.5–25; n  =  17] 
and obese (BMI > 25; n = 19) women with PCOS, and 23 age-
matched lean (n = 7) and obese (n = 16) women without PCOS 
(control), recruited through advertising in the local newspaper, 
were included in the study. The women in the control group had a 
regular menstrual cycle (<35 days) and an androgen level within 
the normal range. None of the participants suffered from other 
chronic diseases or used oral contraceptives or any other drugs 
known to alter glucose or insulin metabolism within the last 
3 months prior to the study. PCOS was diagnosed according to the 
Rotterdam criteria (39), i.e., based on the androgen level, evalu-
ation of hirsutism (Ferriman–Gallwey score ≥8), transvaginal 
ultrasonography, and menstrual history (40). The study design 
and assessment of clinical parameters (PCOS status, anthropo-
metrics, insulin and glucose measurements, lipid profile, and 
hormone analysis) have been previously described (40–44). The 
study was performed at the Department of Endocrinology and 
Department of Obstetrics and Gynecology, Hvidovre University 
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Hospital, Hvidovre, Denmark. The study was approved by the local 
ethics authorities and followed the principles in the “Declaration 
of Helsinki.” All the subjects gave their written informed consent 
prior to the study.
Determination of Body Fat Percentage  
and Measurement of glucose Metabolism, 
lipid Profile, and sex hormones
Participants underwent a dual-emission X-ray absorptiometry 
scan to determine the body fat percentage. Subcutaneous fat 
biopsies for gene expression studies were obtained from the 
lower abdomen. Blood samples were collected following 
an overnight fasting. Plasma glucose was measured using a 
Beckman Glucose analyzer (Ramcon, Fullerton, CA, USA), and 
serum insulin was determined using the 1235 Auto DELPHIA 
Automatic Immunoassay System (Wallac Oy, Turku, Finland). 
The HOMA index was calculated as follows: fasting serum insulin 
concentration (μU/L)  ×  fasting plasma glucose concentration 
(mmol/L)/22.5 (45, 46). Fasting levels of cholesterol, high-density 
lipoprotein (HDL), low-density lipoprotein, very-low-density 
lipoprotein (VLDL), and triglycerides were measured by 
reflection photometry (Ortho-Clinical diagnostics kit, Raritan, 
NJ, USA). Testosterone, DHT, sex hormone-binding globulin 
(SHBG), and the calculation of free testosterone were performed 
as previously described using immunofluorometric assays and 
radioimmunoassays (40).
real-time Polymerase chain reaction 
(Pcr)
RNA was extracted from the fat biopsies using TRIzol (Gibco 
BRL, Life Technologies, Roskilde, Denmark). The concentra-
tion and quality of the purified total RNA were determined 
spectrophotometrically and by running an agarose gel. Reverse 
transcription was performed using the Thermo Scientific Verso 
cDNA kit (Applied Biosystems, Foster City, CA, USA). The 
KAPA SYBR FAST qPCR kit (Kapa Biosystems, Inc., Woburn, 
MA, USA) and a LightCycler 480 (Roche Applied Science, Basel, 
Switzerland) were used for the real-time PCRs. Duplicate reac-
tions of all samples were performed. The expression levels of 
ZIP14, ZIP9, ZNT1, PPARG1, PPARG2, IDE, RBP4, and GLUT4 
were measured. Gene accession numbers and primers are listed 
in Table S1 in Supplementary Material. Low-density lipoprotein 
receptor-related protein-10 (LRP10) was used as a housekeeping 
gene, as it shows a stable expression in human adipose tissue 
(47). The stability of LRP10 was confirmed by statistically com-
paring Ct-cycles between groups. Relative expression levels were 
calculated using the Advanced Relative Quantification mode 
of the LightCycler 480 instrument, version 1.5.0.39 (Roche 
Applied Science).
statistical analysis
Metabolic data and androgen status are presented as the 
means  ±  SD, and the groups were compared by Student’s 
t-test. Data were found to be normally distributed (QQ plots), 
except VLDL and HOMA index values which were log-
transformed to obtain a normal distribution. Real-time PCR 
data are presented as the mean starting quantity of (gene of 
interest/LRP10) ± SEM. Statistical analyses of the PCR results 
were performed on log-transformed data to obtain a normal 
distribution. The influence of PCOS and obesity and their 
interaction with regards to the expression of the genes were 
examined by two-way ANOVA analysis. In the presence of a 
statistically detectable interaction, a combined (interfering) 
effect exists in which the relationship between a factor, e.g., 
weight status and the effect on gene expression differs by the 
presence of the other factor, e.g., PCOS. If statistically signifi-
cant differences were found among the four groups, subgroup 
analyses were performed using Student’s t-test in order to iden-
tify the origins of this difference; e.g., following a significant 
two-way ANOVA showing an effect of obesity, obese PCOS 
women vs. lean PCOS women, and obese control women vs. 
lean control women were compared. Correlations included the 
whole study population (n =  59) and were performed using 
a standard Pearson’s correlation and log-transformed PCR 
data. Although specifically for PPARG1, correlations were 
additionally done separately for PCOS and non-PCOS women, 
as PPARG1 showed a regulation by weight and PCOS status. 
The level of statistical significance in all analyses was set at 
0.05. STATA (StataCorp LP, TX, USA) and GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA, USA) statistical pack-
ages were used for the calculations.
resUlTs
Metabolic Measurements and androgen 
status of PcOs Women and controls
Metabolic and androgen measurements were performed on all 
subjects to establish their metabolic status and to confirm the 
presence or absence of PCOS pathology.
Anthropometric findings, insulin and glucose measurements, 
the lipid profile, and the results of the hormone analysis are shown 
in Table 1. For further details on the metabolic and sex-hormonal 
measurements, please refer to Ref. (40, 41, 43, 44). The age was 
comparable between groups (40). In addition, BMI was similar 
between lean PCOS women and lean controls, and between obese 
PCOS women and obese controls (p = 0.1707 and p = 0.2482, 
respectively). As expected, the HOMA index was significantly 
higher in the obese women than that in lean women in both the 
PCOS and control groups (p = 0.0002 and p < 0.0001, respec-
tively). The total testosterone level was significantly increased in 
the PCOS women compared to the control women in both the 
lean and obese groups (p =  0.01 and p <  0.0001, respectively) 
(40, 41, 43, 44).
In summary, we confirmed the expected differences in BMI, 
HOMA index, and androgen levels of the four groups (lean and 
obese women with and without PCOS), establishing that age did 
not differ significantly among groups nor did BMI differ between 
the obese controls and the obese PCOS women or between lean 
controls and lean PCOS women.
TaBle 1 | Metabolic measurements and androgen status of lean and 
obese women with PcOs, and lean and obese control women without 
PcOs.
PcOs controls
lean PcOs 
(n = 17)
Obese 
PcOs 
(n = 19)
lean controls 
(n = 7)
Obese 
controls 
(n = 16)
Age (years) 28 (±5) 29 (±4) 30 (±4) 31 (±5)
BMI (kg/m2) 23 (±2)●●● 33 (±4) 22 (±2)●●● 34 (±3)
Body fat (%) 27 (±4)●●● 41 (±7) 24 (± 7)●●● 43 (±6)
Insulin (pmol/l) 36 (±18)●● 67 (±39) 25 (±14)●● 64 (±31)
Glucose (mmol/l) 5.5 (±0.4)● 6.0 (±0.6)○ 5.6 (±0.4) 5.6 (±0.3)
HOMA-IR 1.5 (±0.8)●●● 3.0 (±1.8) 1.0 (±0.6)●●● 2.7 (±1.3)
HDL (mmol/l) 1.4 (±0.3)○,●●● 1.1 (±0.2) 1.1 (±0.2) 1.1 (±0.2)
VLDL (mmol/l) 0.4 (±0.2) 0.4 (±0.2) 0.4 (±0.1) 0.6 (±0.3)
Cholesterol 
(mmol/l)
4.3 (±1.0) 4.2 (±0.6) 3.6 (±0.6)●● 4.7 (±0.8)
Triglycerides 
(mmol/l)
0.8 (±0.4) 1.0 (±0.3) 0.8 (±0.2)● 1.2 (±0.6)
T-testosterone 
(nmol/l)
2.1 (±0.8)○ 2.4 (±0.8)○○○ 1.4 (±0.3) 1.4 (±0.4)
F-testosterone 
(nmol/l)
0.034 
(±0.019)○○
0.043 
(±0.022)○○
0.015 
(±0.006)●
0.024 
(±0.007)
SHBG (nmol/l) 67 (±27)○ 59 (±39) 101 (±38)●●● 54 (±21)
Data are presented as the means ± SD.
BMI, body mass index; F-testosterone, free testosterone; HDL, high-density 
lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; PCOS, 
polycystic ovary syndrome; SHBG, sex hormone-binding globulin; T-testosterone, total 
testosterone; VLDL, very-low-density lipoprotein.
○p < 0.05, ○○p < 0.01, ○○○p < 0.001 comparing lean PCOS subjects vs. lean controls 
or obese PCOS subjects vs. obese controls using Student’s t-test.
●p < 0.05, ●●p < 0.01, ●●●p < 0.001 comparing lean PCOS subjects vs. obese PCOS 
subjects or lean controls vs. obese controls.
Level of statistical significance: 0.05.
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ZIP14 and ZNT1 expression are 
Oppositely regulated in Obesity but 
appear Unaffected by PcOs status,  
While ZIP9 expression in adipose Tissue 
is Unaffected in Both Obesity and PcOs
Adipose expression levels of ZIP14, ZIP9, and ZNT1 were inves-
tigated in order to identify if their gene expression is regulated 
by obesity and/or PCOS status, as we have previously reported a 
regulation of obesity on adipose ZIP14 expression (27).
Zinc influx transporter ZIP14 and zinc efflux transporter 
ZNT1 expression were oppositely regulated in obese women. 
ZIP14 expression decreased significantly in obese individuals 
compared with lean individuals by two-way ANOVA analysis 
(p < 0.0001; subgroup analysis examining lean PCOS vs. obese 
PCOS, and lean controls vs. obese controls using Student’s t-test; 
p = 0.0008 and p = 0.0079, respectively). Neither PCOS status 
(p = 0.3892) nor any combinatory influence of PCOS and weight 
status had a significant effect on ZIP14 expression by two-way 
ANOVA analysis (p = 0.6908) (Figure 1A).
Obesity showed a significant upregulatory effect on ZNT1 
expression by two-way ANOVA analysis (p = 0.0177; subgroup 
analysis examining lean PCOS vs. obese PCOS, and lean con-
trols vs. obese controls using Student’s t-test; p =  0.0169 and 
p =  0.2489, respectively). However, PCOS status did not relate 
to ZNT1 expression, and no combinatory effect between PCOS 
status and weight was found with regards to ZNT1 expression lev-
els using two-way ANOVA analysis (p = 0.3577 and p = 0.6396, 
respectively) (Figure 1B).
ZIP9 expression was unaffected by both obesity and PCOS 
status, and no combinatory effect between the two parameters 
was seen by two-way ANOVA analysis (p = 0.4764, p = 0.8036, 
and p = 0.3516, respectively) (Figure 1C).
In conclusion, ZIP14 and ZNT1 were oppositely regulated 
by obesity, with a downregulation of ZIP14 and upregulation of 
ZNT1, but the adipose expression of these zinc transporters was 
not significantly altered by PCOS status.
PPARG1 expression in adipose Tissue is 
Downregulated by Both Obesity and PcOs
With a known function in lipid and glucose metabolism as well 
as a role in adipogenesis, adipose PPARG expression levels (both 
isoforms 1 and 2) were investigated in terms of a potential regula-
tion of these genes by PCOS status alone or in combination with 
obesity.
The mRNA isoforms PPARG1 and PPARG2 were inves-
tigated. Two-way ANOVA analysis showed a significant 
downregulation of PPARG1 expression by obesity (p < 0.0001; 
subgroup analysis examining lean PCOS vs. obese PCOS, 
and lean controls vs. obese controls using Student’s t-test; 
p =  0.0001 and p <  0.0001, respectively). In addition, two-
way ANOVA testing showed a significant downregulatory 
effect of PCOS on PPARG1 expression (p = 0.0291; subgroup 
analysis examining lean PCOS vs. lean controls, and obese 
PCOS vs. obese controls using Student’s t-test; p = 0.0045 and 
p =  0.5380, respectively). However, no additional combined 
effect of PCOS and weight status was found with regards to 
PPARG1 expression (p  =  0.1739) (Figure  2A). Two-way 
ANOVA showed no significant effect of weight or PCOS status, 
nor any combined effect of the two on PPARG2 expression 
(p = 0.2021, p = 0.1244, and p = 0.0701, respectively). Notably, 
mean expression levels were highest in lean controls, as found 
for PPARG1 (Figure 2B).
In summary, the expression of PPARG1 was significantly 
downregulated by the presence of PCOS as well as by the presence 
of obesity. However, the combined effect of PCOS and obesity 
did not statistically differ from the presence of just one of these 
conditions. Statistically, PPARG2 showed no regulation by PCOS 
or obesity status, but showed a similar expression pattern to that 
of PPARG1 with a high expression in lean controls compared to 
the other groups, indicating a potential negative effect of PCOS 
and obesity.
expression of ZIP14 in adipose Tissue is 
correlated with PPARG, BMi, and Body 
Fat Percentage
As ZIP14 expression levels were found to be regulated by obesity 
and ZIP14 is believed to play a role in adipogenesis, the association 
with the measured metabolic markers was investigated in terms 
FigUre 2 | expression of peroxisome proliferator-activated receptor gamma (PParg) in adipose tissue from lean and obese women with polycystic 
ovary syndrome (PcOs), and from lean and obese control women without PcOs. Results are expressed as the mean starting quantity of (gene of 
interest/LRP10) ± SEM. (a) Expression of PPARG1. (B) Expression of PPARG2. **p < 0.01; ***p < 0.001. LRP10, low-density lipoprotein receptor-related 
protein-10; PPARG1, peroxisome proliferator-activated receptor gamma mRNA isoform 1; PPARG2, peroxisome proliferator-activated receptor gamma mRNA 
isoform 2. Lean PCOS women, n = 17; obese PCOS women, n = 19; lean control women, n = 7; obese control women, n = 16. The groups were compared by 
two-way ANOVA analysis followed by subgroup analysis by Student’s t-test if significant. Level of statistical significance: 0.05.
FigUre 1 | expression of zinc transporters ZIP14, ZNT1, and ZIP9 in adipose tissue from lean and obese women with polycystic ovary syndrome 
(PcOs), and from lean and obese control women without PcOs. Results are expressed as the mean starting quantity of (gene of interest/LRP10) ± SEM.  
(a) Expression of ZIP14. (B) Expression of ZNT1. (c) Expression of ZIP9. *p < 0.05; **p < 0.01; ***p < 0.001. LRP10, low-density lipoprotein receptor-related 
protein-10. Lean PCOS women, n = 17; obese PCOS women, n = 19; lean control women, n = 7; obese control women, n = 16. The groups were compared by 
two-way ANOVA analysis followed by subgroup analysis by Student’s t-test if significant. Level of statistical significance: 0.05.
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of the correlation between ZIP14 expression and anthropometric 
measurements, lipid profile, and adipogenesis marker PPARG 
using Pearson’s correlation.
ZIP14 expression associated closely with that of PPARG, with 
a significant positive correlation between the two genes, for both 
PPARG1 and PPARG2 levels (p = 0.0001, and p = 0.0046, respec-
tively). When investigating the correlation between PPARG1 and 
ZIP14 expression separately for PCOS and non-PCOS women, 
as PPARG1 was shown to be statistically independently affected 
by PCOS status, similar correlations were found (PCOS: r = 0.49, 
p = 0.0022; non-PCOS: r = 0.48, p = 0.0210).
ZIP14 expression showed a strong inverse correlation 
with the anthropometric markers BMI (p =  0.0001) and body 
fat percentage (p =  0.0027). With regard to the lipid profile, 
ZIP14 expression showed a positive correlation with the 
HDL level (p  =  0.0421), but no significant correlations were 
found with other lipid profile markers (VLDL, triglyceride, 
or cholesterol levels). All r-values and p-values are shown in 
Table 2.
In summary, ZIP14 showed a close inverse relationship with 
anthropometric markers of obesity as well as a positive associa-
tion with the adipose expression of PPARG.
TaBle 2 | correlations among ZIP14 expression and anthropometric 
parameters, markers of lipid and glucose homeostasis, and markers of 
androgen function.
ZIP14 expression
PPARG1 r = 0.48, p = 0.0001
PPARG2 r = 0.36, p = 0.0046
BMI r = −0.47, p = 0.0001
Body fat percentage r = −0.39, p = 0.0027
Insulin r = −0.09, p = 0.4955
Glucose r = −0.32, p = 0.0120
HOMA-IR r = −0.23, p = 0.0822
HDL r = 0.27, p = 0.0421
VLDL r = 0.01, p = 0.9238
Triglyceride r = −0.00, p = 0.9748
Cholesterol r = −0.02, p = 0.8888
T-testosterone r = −0.10, p = 0.4617
F-testosterone r = −0.34, p = 0.1070
SHBG r = 0.16, p = 0.2169
Ferriman–Gallwey r = −0.14, p = 0.2849
RBP4 expression r = 0.33, p = 0.0117
GLUT4 expression r = 0.42, p = 0.0009
All women were included (n = 59) in this analysis. Pearson’s r-values and p-values are 
indicated. Level of statistical significance: 0.05.
BMI, body mass index; F-testosterone, free testosterone; GLUT4, glucose transporter 
4; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin 
resistance; PPARG, peroxisome proliferator-activated receptor gamma; RBP4, 
retinol-binding protein 4; SHBG, sex hormone-binding globulin; T-testosterone, total 
testosterone; and VLDL, very-low-density lipoprotein.
TaBle 3 | correlations among ZNT1 expression and anthropometric 
parameters, markers of lipid and glucose homeostasis, and markers of 
androgen function.
ZNT1 expression
PPARG1 r = −0.16, p = 0.2311
PPARG2 r = 0.18, p = 0.1826
BMI r = 0.30, p = 0.0199
Body fat percentage r = 0.32, p = 0.0140
Insulin r = 0.29, p = 0.0277
Glucose r = 0.16, p = 0.2268
HOMA-IR r = 0.30, p = 0.0213
HDL r = −0.26, p = 0.0468
VLDL r = 0.10, p = 0.4634
Triglyceride r = 0.15, p = 0.2423
Cholesterol r = −0.01, p = 0.9125
T-testosterone r = 0.15, p = 0.2423
F-testosterone r = 0.03, p = 0.8006
SHBG r = 0.02, p = 0.8886
Ferriman–Gallwey r = 0.10, p = 0.4377
RBP4 expression r = 0.01, p = 0.9437
GLUT4 expression r = 0.05, p = 0.6917
All women (n = 59) were included in the analysis. Pearson’s r-values and p-values are 
indicated. Level of statistical significance: 0.05.
BMI, body mass index; F-testosterone, free testosterone; GLUT4, glucose transporter 
4; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin 
resistance; PPARG, peroxisome proliferator-activated receptor gamma; RBP4, 
retinol-binding protein 4; SHBG, sex hormone-binding globulin; T-testosterone, total 
testosterone; and VLDL, very-low-density lipoprotein.
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ZIP14 expression in adipose Tissue is 
significantly correlated with several 
Markers of glucose Metabolism in Blood 
as Well as in adipose Tissue, but not with 
PcOs Markers
As ZIP14 expression was found to be regulated by obesity, in 
which alterations in glucose homeostasis are found, we tested 
a potential association between ZIP14 expression and glucose 
homeostatic markers. Further we aimed at confirming that ZIP14 
expression levels do not associate with PCOS status by investigat-
ing the association between ZIP14 expression and specific PCOS 
markers.
With regard to glucose metabolism, ZIP14 inversely cor-
related with fasting glucose levels (p = 0.0120). However, ZIP14 
showed no significant correlation with fasting insulin levels 
or the HOMA index; although in the latter case, the correla-
tion did approach significance (p =  0.0822). In adipose tissue, 
ZIP14 expression showed significant positive correlations with 
the glucose metabolic markers, RBP4 (p = 0.0117) and GLUT4 
(p = 0.0009). ZIP14 expression showed no correlation with the 
PCOS indicators, namely, testosterone, SHBG, or the Ferriman–
Gallwey score of hirsutism. All r-values and p-values are shown 
in Table 2.
In short, using a Pearson’s correlation, ZIP14 showed an 
association with glucose homeostatic markers in adipose tissue 
and fasting glucose levels. No association was found with specific 
PCOS markers, confirming the statistical findings of the two-way 
ANOVA analysis.
ZNT1 showed associations That Were 
Opposite to Those of ZIP14 with BMi  
and Body Fat Percentage
As the main zinc efflux transporter at the cell membrane, and due to 
its opposite regulation than ZIP14 by obesity, we investigated if ZNT1 
expression was associated with the same parameters as ZIP14, in terms 
of anthropometric markers, lipid profile, and PPARG levels.
Using Pearson’s correlation, ZNT1 showed associations that were 
opposite to those of ZIP14 with the measured anthropometric mark-
ers, as ZNT1 expression displayed a significant positive correlation 
with BMI (p = 0.0199) and body fat percentage (p = 0.0140). However, 
ZNT1 expression did not associate with the two PPARG isoforms 
(PPARG1, p = 0.2311; PPARG2, p = 0.1826), although when analyzing 
non-PCOS and PCOS women separately, as for ZIP14, a significant 
correlation with PPARG1 was observed in PCOS women (r = −0.34, 
p = 0.0401) but not in non-PCOS women (r = 0.13, p = 0.5685). 
The correlation of ZNT1 expression with the lipid profile showed a 
negative association with HDL (p = 0.0468). No other significant cor-
relations were found. All r-values and p-values are shown in Table 3.
In summary, ZNT1 showed an opposite association, to that 
of ZIP14, in terms of the anthropometric markers, but with no 
general association to PPARG expression levels, aside from the 
subgroup analysis of PCOS women only.
Markers of glucose homeostasis 
significantly correlated with ZNT1 
expression
As ZNT1 expression showed an opposite regulation by obesity 
than that of ZIP14, expression levels of ZNT1 were correlated 
FigUre 3 | expression of markers of glucose metabolism in adipose tissue from lean and obese women with polycystic ovary syndrome (PcOs), 
and from lean and obese control women without PcOs. Results are expressed as the mean starting quantity of (gene of interest/LRP10) ± SEM.  
(a) Expression of RBP4. (B) Expression of GLUT4. (c) Expression of IDE. *p < 0.05; ***p < 0.001. GLUT4, glucose transporter 4; LRP10, low-density lipoprotein 
receptor-related protein-10; RBP4, retinol-binding protein 4; and IDE, insulin degrading enzyme. Lean PCOS women, n = 17; obese PCOS women, n = 19; lean 
control women, n = 7; obese control women, n = 16. The groups were compared by two-way ANOVA analysis followed by subgroup analysis by Student’s t-test if 
significant. Level of statistical significance: 0.05.
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with glucose homeostasis and markers specifically associated 
with PCOS, to investigate if ZNT1 associated with the same 
parameters as ZIP14 using a Pearson’s correlation.
Of the markers of glucose homeostasis in the blood and 
adipose tissue, ZNT1 showed a significant positive correlation 
with the fasting insulin level (p = 0.0277) and the HOMA index 
(p =  0.0213). There was no statistical significant correlation of 
ZNT1 expression with fasting glucose levels or RBP4 and GLUT4 
expression in adipose tissue. ZNT1 showed no statistical sig-
nificant correlations with PCOS indicators, namely, testosterone, 
SHBG, or the Ferriman–Gallwey score of hirsutism. All r-values 
and p-values are shown in Table 3.
In summary, ZNT1 showed a correlation with blood glucose 
homeostatic markers, rather than markers of glucose homeostasis 
in adipose tissue. Confirming the results of the two-way ANOVA 
analysis, no association of ZNT1 expression was found with 
PCOS markers.
RBP4 and GLUT4 expression is 
Downregulated in adipose Tissue in 
Obese Women, with PcOs status 
affecting the RBP4 level, While IDE 
expression is Unaffected by Obesity and 
PcOs status
As markers of glucose homeostasis within adipose tissue, RBP4, 
GLUT4, and IDE are all associated with the presence of insulin 
resistance. With insulin resistance being a feature of PCOS as well 
as a comorbid factor of obesity, we investigated if PCOS affect 
their expression in adipose tissue directly and if the presence of 
obesity can cause a similar change or affect any PCOS induced 
alterations in the expression of these genes.
A markedly higher RBP4 expression was seen in lean controls 
compared to the other three groups which appeared similar (lean 
and obese PCOS women as well as obese controls) (Figure 3A). 
Supporting this, two-way ANOVA confirmed a significant inter-
action between weight and PCOS status (p = 0.0185), reflecting 
that PCOS status plays a role on RPB4 expression and that this 
role depends on weight status, as no effect of PCOS per se was 
found (p = 0.1544, two-way ANOVA). In line with this, subgroup 
analysis using Student’s t-test showed a significant difference 
between lean PCOS and lean controls (p =  0.0170, t-test), but 
not between obese PCOS and obese controls (p =  0.4188), as 
a downregulatory effect similar to the one of PCOS was found 
of obesity (p = 0.0010, two-way ANOVA). According to this, a 
significant difference was seen when comparing obese controls 
vs. lean controls (p = 0.0002, t-test) whereas no difference was 
found when comparing obese PCOS women vs. lean PCOS 
women (p = 0.4286, t-test).
As shown by the two-way ANOVA analysis, the adipose 
expression of GLUT4 was significantly downregulated by the pres-
ence of obesity (p = 0.0009), evident in subgroup analysis using 
Student’s t-test when comparing obese controls vs. lean controls 
(p = 0.0185, t-test) and tending toward statistically significance 
when comparing lean PCOS vs. obese PCOS (p = 0.0547, t-test). 
Two-way ANOVA analysis found no statistically significant effect 
of PCOS status on GLUT4 expression (p = 0.1997) nor any statis-
tical interaction between PCOS status and obesity (p = 0.1318), 
although GLUT4 expression levels were higher in women in the 
lean control group than in any of the other three groups, as noted 
for RBP4 (Figure 3B).
There were no statistical significant effects of PCOS status or 
obesity nor any interaction effect between the two on IDE expres-
sion levels by two-way ANOVA analysis (p = 0.9489, p = 0.6998 
and p = 0.3055, respectively) (Figure 3C).
In summary, for RBP4 expression, a high level was observed 
within the group of lean women compared to all other groups, 
which appeared similar, corresponding to a downregulatory 
response in lean PCOS women similar to the one observed 
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when obese, and reflected as a statistically significant interaction 
between obesity and PCOS status. Likewise, expression of GLUT4 
was high in lean women compared to the other groups, indicat-
ing a potential effect of obesity and PCOS status, although only 
statistically significant of obesity on GLUT4 expression.
DiscUssiOn
Reduced levels of circulating zinc are common in obesity (8, 9) 
whereas recent studies report conflicting results with regard to 
the levels of circulating zinc in the blood of PCOS women (3–5). 
However, zinc supplementation has several beneficial effects 
on the metabolic status in PCOS women (6, 48). So far, limited 
attempts have been made to understand the underlying molecular 
events of the zinc disturbances in PCOS.
Investigating the expression of the zinc transporter ZIP14 
in adipose tissue, we found that ZIP14 expression decreased in 
obese women with and without PCOS. Though, there was no 
statistically significant effect of PCOS itself on ZIP14 expression. 
This correlation between the body weight and ZIP14 expres-
sion supports our previous study of ZIP14 in adipose tissue 
from otherwise healthy men and women, in which we found 
that ZIP14 is downregulated in subcutaneous fat in response to 
obesity and that the downregulation is reversed by weight loss 
(27). Downregulation of ZIP14 in a chronic condition with low-
grade inflammation such as obesity might appear paradoxical, 
as murine studies have shown an upregulation of Zip14 expres-
sion in liver, muscle, and adipose tissue after exposure to the 
pro-inflammatory lipopolysaccharide (29, 49). Studies in Zip14 
knockout mice have linked lack of this specific transporter to 
inflammation, with evidence of endotoxemia and increased levels 
of circulating pro-inflammatory cytokines (29).
Moreover, Zip14 knockouts have increased amounts of body 
fat and display hypertrophic adipocytes with low differentiation 
potential in adipose tissues (29). Studies of 3T3-L1 pre-adipocytes 
confirm that Zip14 is associated with adipocyte differentiation 
(27–29), and that mobilization of intracellular zinc is decreased 
in adipocytes with downregulated Zip14 expression (29).
The downregulation of Zip14 in adipocytes is speculated to 
result in a lack of free cytoplasmic zinc in adipocytes, defined as 
“the zinc trap” (29) by Troche and coworkers. The zinc trap refers 
to the fact that downregulation of Zip14 in 3T3-L1 adipocytes 
increases vesicular zinc yet reduces metallothionein expres-
sion (29). As metallothionein expression is tightly regulated by 
cytoplasmic zinc ions such low expression of metallothionein is 
considered indicative of a low concentration of free cytoplasmic 
zinc (50).
Although the present study employs fatty tissue samples as a 
whole—which includes macrophage involvement—our findings 
support a condition of cytoplasmic zinc deficiency within adipo-
cytes in obesity, as we see downregulation of ZIP14 paralleled by 
an upregulation of ZNT1, the only SLC30A efflux transporter in 
the plasma membrane (51). Supporting an obesity-related zinc 
dyshomeostasis, a reduced expression of ZIP1–8 and ZNT 2, 3, 
6, and 8 has previously been described in subcutaneous fat from 
obese individuals (52). However, such changes in zinc homeosta-
sis are likely to be tissue specific. We recently reported decreased 
ZNT1 and ZNT6 expression in the human frontal cortex with 
increased BMI (53), and differences have been noted when 
comparing subcutaneous and visceral adipose tissues (52, 54). An 
altered expression of zinc transporters indicates a change in the 
pico-molar concentration and distribution of free intracellular 
zinc, but it is questionable if it will result in a measurable change 
in total zinc concentration within the range of a few 100 micro-
molar. We have previously shown comparable levels of total zinc 
in adipose tissue from diabetic and non-diabetic sand rats on 
a high energy diet, as well as in blood samples from obese and 
non-obese individuals, despite changes in the expression profile 
of zinc transporters in adipose tissue (27, 54). Ultra-structural 
analysis of fresh tissue samples using the highly sensitive auto-
metallographic technique might in the future provide valuable 
insights on the in situ location of free or loosely bound zinc (55); 
however, this method of silver amplification cannot be used for 
quantitative measurements.
The adipogenic transcription factor PPARG (56) links with 
PCOS, as specific PPARG gene polymorphisms associate with a 
reduced risk of PCOS and a better metabolic profile in PCOS 
women (31, 32). PPARG agonists are also used therapeutically 
in PCOS as it improves menstrual cyclicity, hormone levels, and 
glucose homeostasis (57). We observed that both obesity and 
PCOS reduce PPARG expression. Studies in adipocyte cultures, 
human biopsies, and tissues from Zip14 knockout mice have all 
shown a positive association between PPARG and ZIP14 expres-
sion in adipose tissue (27, 29). Thus, Zip14 knockout mice display 
a decreased PPARG level and increased adipose tissue hypertro-
phy (29), indicating that the lack of free cytoplasmic zinc affects 
PPARG levels in these mice. Accordingly, free cytoplasmic zinc 
participates in cell differentiation by regulating different signal-
ing pathways and transcription factors (58). Moreover, PPARG 
signaling and expression is decreased upon zinc deficiency and 
PPARG structurally requires zinc ions (33, 34). Therefore, it is 
likely that the PPARG downregulation occurring in obese indi-
viduals is caused by the decrease in ZIP14 and upregulation of 
ZNT1. We found no synergistic effect between obesity and PCOS 
with regard to PPARG expression. In a larger study, however, it 
cannot be excluded that an association exists. PPARG expression 
was significantly reduced in lean women with PCOS, despite an 
unaltered ZIP14 expression level, compared to lean controls, 
indicating that another signaling pathway could affect PPARG in 
PCOS. The high androgen level in PCOS women could account 
for some of the PPARG alterations, as androgens can decrease 
PPARG expression, as well as adipogenesis (59, 60).
Similar to ZIP14, GLUT4 and RBP4 expression are reduced 
in obesity. A statistically significant synergistic effect of PCOS 
and obesity was found for RBP4, and although not statistically 
significant for GLUT4, the lean controls appeared to be substan-
tially different from both PCOS groups with regards to GLUT4 
expression. The obesity-related changes in these two genes could 
partly reflect a reduction in free cytoplasmic zinc. GLUT4 levels 
are downregulated in an obese insulin-resistant state (61) and 
regulated by the insulin signaling pathway (62), in which free 
intracellular zinc regulates several signaling steps (63). Zinc can 
also affect the transport/release of retinol and alter RBP4 levels 
in liver (64, 65). RBP4 has been speculated to be involved in 
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inflammation and insulin resistance in obesity and type 2 diabetes 
(66), but the exact role and regulation in obesity is so far unclear 
(67). Increased RBP4 levels have been reported in adipose tissue 
from obese PCOS women vs. obese controls (68). In this study, 
RBP4 expression was higher in the obese PCOS group vs. obese 
controls, although the change was not statistically significant with 
the present sample size.
ZIP14 seem to affect glucose metabolism as Zip14 knockout 
mice display hyperinsulinemia, augmented insulin receptor 
phosphorylation, and increased liver glucose (49, 69). ZIP14 
might thus affect the symptomatology of PCOS via organs other 
than white fatty tissue. In this study, ZIP14 expression in sub-
cutaneous fat associates with markers of glucose metabolism in 
both blood and adipose tissue, although not as significantly as our 
previous findings in which the HOMA index, fasting glucose, and 
insulin correlated with ZIP14 expression. However, our previous 
study included subjects of both sexes which had a higher average 
BMI in the obese group (27). As for ZIP14, the expression of the 
counter-regulated influx transporter ZNT1 also showed signifi-
cant correlations with markers of glucose homeostasis, further 
linking alterations in intracellular zinc to glucose metabolism.
Sex hormones regulate zinc transporters of the LIV-1 sub-
family, and ZIP14 expression can be induced by estrogen (26). 
However, we found no evidence that the specific hormonal 
changes occurring in PCOS affect ZIP14 expression in adipose 
tissue. Furthermore, there were no changes in ZIP9 expression, 
even though this transporter can function as an androgen receptor 
(37). Likely, obesity has a stronger influence on zinc homeostasis 
than the altered hormonal levels in PCOS.
In conclusion, PCOS is a complex disease that involves a 
zinc homeostatic disturbance and adipocyte dysfunction. The 
zinc transporters ZNT1 and ZIP14 show an inverse regulation 
in subcutaneous adipose tissue in obesity, as well as in obese 
women with PCOS. The downregulation of ZIP14 expression 
and the upregulation of ZNT1 expression in obese subjects are 
indicative of a reduction in free cytoplasmic zinc, with potential 
down-stream effects on PPARG, RBP4, and GLUT4 expression, as 
well as RBP4 appear to be directly involved in PCOS pathology.
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